Stock Code: 000028/200028 Notice No.: 2021-34Short Form of the Stock: Sinopharm Accord /Accord B
China National Accord Medicines Corporation Ltd.
Summary of Semi-Annual Report 2021I. Important NoticeThe summary of semi-annual report is excerpted from the full text of the semi-annual report. For the details, investors shouldcarefully read the full text of the semi-annual report published on Juchao Information website (www.cninfo.com.cn) and ShenzhenStock Exchange Website etc., appointed by CSRC.Other directors attending the Meeting for semi-annual report deliberation except for the followed
| Name of director absent | Title for absent director | Reasons for absent | Attorney |
Prompt of modified auditing opinion
□ Applicable √ Not applicable
Profit distribution pre-plan of common stock or capitalizing of common reserves pre-plan deliberated by the Board in the reportingperiod
□ Applicable √ Not applicable
The Company plans not to carry out cash dividend and bonus distribution and capitalizing of common reservesProfit distribution pre-plan of preferred stock deliberated and approved by the Board in the reporting period
□ Applicable √ Not applicable
II. Basic information of the company
1. Company profile
| Short form of the stock | Sinopharm Accord, Accord B | Stock code | 000028, 200028 | |
| Stock exchange for listing | Shenzhen Stock Exchange | |||
| Person/Way to contact | Secretary of the Board | Rep. of security affairs | ||
| Name | Chen Changbing | Wang Zhaoyu | ||
| Office add. | Accord Pharm. Bldg., No. 15, Ba Gua Si Road, Futian District, Shenzhen, Guangdong Province | Accord Pharm. Bldg., No. 15, Ba Gua Si Road, Futian District, Shenzhen, Guangdong Province | ||
| Tel. | +(86)755 25875195 | +(86)755 25875222 | ||
| gyyzinvestor@sinopharm.com | gyyz0028@sinopharm.com | |||
2. Main financial data and index
Whether it has retroactive adjustment or re-statement on previous accounting data
□ Yes √ No
| Current Period | Same period of last year | Increase/decrease in this report y-o-y | |
| Operating revenue (RMB) | 33,163,091,887.39 | 27,169,940,188.52 | 22.06% |
| Net profit attributable to shareholders of the listed Company (RMB) | 741,445,013.25 | 643,451,580.59 | 15.23% |
| Net profit attributable to shareholders of the listed Company after deducting non-recurring gains and losses (RMB) | 720,954,408.22 | 627,017,019.45 | 14.98% |
| Net cash flow arising from operating activities (RMB) | 1,229,373,283.57 | 1,438,204,043.35 | -14.52% |
| Basic earnings per share (RMB/Share) (note 1) | 1.73 | 1.50 | 15.33% |
| Diluted earnings per share (RMB/Share) | 1.73 | 1.50 | 15.33% |
| Weighted average ROE | 5.22% | 4.91% | Increase 0.31 percentage points |
| End of current period | End of last period | Increase/decrease in this report-end over that of last period-end (+,-) | |
| Total assets (RMB) | 44,190,878,403.95 | 39,594,533,471.65 | 11.61% |
| Net assets attributable to shareholder of listed Company (RMB) | 14,346,870,065.79 | 13,948,322,652.33 | 2.86% |
3. Number of shareholders and share-holding
Unit: share
| Total common shareholders at period-end | 43,600 | Total preference shareholders with voting rights recovered at end of reporting period (if applicable) | 0 | ||||
| Top ten shareholders | |||||||
| Full name of Shareholders | Nature of shareholder | Proportion of shares held | Amount of shares held | Amount of restricted shares held | Information of shares pledged, tagged or frozen | ||
| State of share | Amount | ||||||
| Sinopharm Group Co., Ltd. | State-owned Corporation | 56.06% | 239,999,991 | 5,505,770 | |||
| FIRST SENTIER INVESTORS GLOBAL UMBRELLA FUND PLC - FSSA CHINA GROWTH FUND | Foreign Corporation | 2.68% | 11,469,644 | ||||
| Hong Kong Securities Clearing Company Ltd | Foreign Corporation | 2.58% | 11,033,948 | ||||
| China National Pharmaceutical Foreign Trade Corp. | State-owned Corporation | 1.24% | 5,323,043 | |||
| National Social Security Fund 413 Portfolio | Domestic non state-owned Corporation | 0.98% | 4,200,032 | |||
| BBH BOS S/A FIDELITY FD - CHINA FOCUS FD | Foreign Corporation | 0.78% | 3,358,761 | |||
| China Construction Bank Corporation -China Europe Value Discovery Equity Fund | Domestic non state-owned Corporation | 0.73% | 3,111,875 | |||
| CPIC Fund -China Pacific Life Insurance Co., Ltd. - with-profit insurance- CPIC Fund China Pacific Life Equity Relative Income (Guaranteed Dividend) single assets management plan | Domestic non state-owned Corporation | 0.66% | 2,822,801 | |||
| Fidelity Investment Management (Hong Kong) Limited - Client’s fund | Foreign Corporation | 0.54% | 2,308,237 | |||
| VANGUARD EMERGING MARKETS STOCK INDEX FUND | Foreign Corporation | 0.41% | 1,756,387 | |||
| Explanation on associated relationship among the aforesaid shareholders | Sinopharm Group Co., Ltd. and China National Pharmaceutical Foreign Trade Corporation have the same actual controller, which is China National Pharmaceutical Group Corporation. It is unknown that there exists no associated relationship or belongs to the consistent actionist among the other tradable shareholders regulated by the Management Measure of Information Disclosure on Change of Shareholding for Listed Companies. | |||||
4. Changes of controlling shareholders or actual controller
Changes of controlling shareholders in reporting period
□ Applicable √ Not applicable
Changes of controlling shareholders had no change in reporting period.Changes of actual controller in reporting period
□ Applicable √ Not applicable
Changes of actual controller had no change in reporting period.
5. Total preferred stock shareholders of the Company and shares held by top ten shareholders withpreferred stock held
□ Applicable √ Not applicable
The Company had no shareholders with preferred stock held in the reporting.
6. Bonds in existence as of the approval date of the semi-annual report
□ Applicable √ Not applicable
III. Important eventsNil